Navigation Links
BD Statement Regarding Impact of Japan Earthquake
Date:3/15/2011

FRANKLIN LAKES, N.J., March 15, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) has operations in Japan led by its Nippon Becton Dickinson headquarters office in Tokyo, and a manufacturing facility and distribution center in Fukushima prefecture.  The Company today confirmed that all of its employees in Japan are safe and that its office in Tokyo is undamaged and functional. BD's manufacturing plant and distribution center in Fukushima are temporarily closed while the Company assesses damage, which does not appear to be extensive.  BD is also in the process of evaluating access to utilities and transportation, which have been impacted throughout Japan due to the earthquake and tsunami. BD sources certain component parts and finished products from third-party suppliers in Japan, and currently believes that inventories of these items will be sufficient to meet global demand until supply chain interruptions are resolved.

Revenues in Japan represented approximately 5 percent of BD's fiscal year 2010 revenues.  Revenues from products manufactured in Japan (BD Hypak™ Prefillable Syringes and prepared plated media) represented approximately 1 percent of BD's fiscal year 2010 revenues.

BD is actively engaged with many disaster relief organizations in supporting the humanitarian aid effort.

About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com. Contact:Colleen T. White, Corporate Communications – 201-847-5369Zachary A. Nagle, Investor Relations – 201-847-5453
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Assured Pharmacy Completes Audit of 2008-2009 Financial Statements
2. Statement: PILMA Applauds Senate Passage of Patent Reform
3. The FDA Releases a Public Health Statement on Metal-on-Metal Hip Implants
4. Nephros Rights Offering Registration Statement Declared Effective
5. Vanda Pharmaceuticals Files Shelf Registration Statement
6. Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA
7. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
8. Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
9. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
10. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
11. Cannabis Science Files Preliminary 14c Information Statement, the Action is to Create a New Class of Common Stock and Issue Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):